Generics of SGLT-2 inhibitory diabetes treatment Jardiance (Empagliflozin, Beringer Ingelheim, Korea) have obtained a number of generic for exclusivity. The number of target items alone amounts to 93. Most of the licensed products have won generic for exclusivity. It will be applied for nine months from October 24, 2025, the date of sale.

According to the MFDS on the 29th, 93 generics for Jardiance acquired generic for exclusivity as of the 27th. The effective date is from October 24, 2025, when Jardiance's substance license ends.

The generic for exclusivity is granted to the first applicant for permission after the patent challenge is successful challenge. It can be said that all 93 com